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Abstract
Background: Previous reports have suggested that advanced glycation end products (AGEs) participate in the
pathogenesis of diabetic macroangiopathy. Our previous study have found that AGEs can increase the lipid droplets
accumulation in aortas of diabetic rats, but the current understanding of the mechanisms remains incomplete by
which AGEs affect lipids accumulation in macrophages and accelerate atherosclerosis. In this study, we investigated the
role of AGEs on lipids accumulation in macrophages and the possible molecular mechanisms including cholesterol
influx, esterification and efflux of macrophages.
Methods: THP-1 cells were incubated with PMA to differentiate to be macrophages which were treated with
AGEs in the concentration of 300 μg/ml and 600 μg/ml with or without anti-RAGE (receptor for AGEs) antibody
and then stimulated by oxidized-LDL (oxLDL) or Dil-oxLDL. Lipids accumulation was examined by oil red staining.
The cholesterol uptake, esterification and efflux were detected respectively by fluorescence microscope, enzymatic
assay kit and fluorescence microplate. Quantitative RT-PCR and Western blot were used to measure expression of the
moleculars involved in cholesterol uptake, synthesis/esterification and efflux.
Results: AGEs increased lipids accumulation in macrophages in a concentration-dependent manner. 600 μg/ml
AGEs obviously upregulated oxLDL uptake, increased levels of cholesterol ester in macrophages, and decreased
the HDL-mediated cholesterol efflux by regulating the main molecular expression including CD36, Scavenger
receptors (SR) A2, HMG-CoA reductase (HMGCR), ACAT1 and ATP-binding cassette transporter G1 (ABCG1). The
changes above were inversed when the cells were pretreated with anti-RAGE antibody.
Conclusions: The current study suggest that AGEs can increase lipids accumulation in macrophages by regulating
cholesterol uptake, esterification and efflux mainly through binding with RAGE, which provide a deep understanding of
mechanisms how AGEs accelerating diabetic atherogenesis.
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Background
It is well established that people with diabetes mellitus
have a greater risk of cardiovascular morbidity and mor-
tality than their normal counterparts. More than 50 % of
diabetes-related deaths are associated with macrovascu-
lar complications, especially atherosclerosis [1]. Multiple
risk factors are associated with atherosclerosis, including
hyperglycemia, hyperlipidemia, and dysregulation of the
angiotensin system [2, 3]. Recent studies show that oxida-
tive stress and advanced glycation also play an important
role in the development of diabetic macrovascular dis-
ease [4, 5]. Advanced glycation end products (AGEs), a
heterogeneous group of complex structures, form non-
enzymatically when reducing sugars react with free
amino groups on proteins, lipids, or nucleic acids. AGEs
formation and accumulation, processes of normal aging
driven by hyperglycemia, occur at an accelerated rate in
diabetic patients and may participate in the pathogenesis
of diabetic vascular disease [6]. The interaction between
AGEs and its receptor, RAGE, contributes to the pro-
gression of atherosclerosis and accelerates oxidative
stress [7–10]. RAGE, a member of the immunoglobulin
superfamily of cell surface molecules, is a multi-ligand
receptor on vascular cells that plays a key role in in-
flammatory processes [11]. Unlike other receptors that
are downregulated by increased levels of their ligands,
the RAGE-ligand interaction leads to positive feedback
activation which further increases receptor expression
[12]. There is increasing evidence that in diabetic pa-
tients, activation of the AGEs-RAGE pathway plays a
central role in the cascade of events that result in accel-
erated atherosclerotic plaque formation, plaque erosion
and fissuring [13, 14].
Atherosclerosis is a chronic disease characterized by the
deposition of excessive cholesterol in the arterial intima.
Macrophage foam cells play a critical role in the occur-
rence and development of atherosclerosis. Macrophage
cholesterol homeostasis maintenance is the result of a
balance among influx, endogenous synthesis, catabolism,
and efflux [15]. Scavenger receptors (SRs), CD36 and SR
class A (SR-A) are the principal receptors responsible for
the binding and uptake of ox-LDL in macrophages [16].
ACAT1 and neutral cholesteryl ester hydrolase (nCEH)
play a critical role in cholesterol esterification [17].
ATP-binding cassette (ABC) transporter A1(ABCA1),
ABCG1 and SR-BI mediate cholesterol export from mac-
rophages [18]. Expressions of ABCA1, ABCG1 and apoE
are mediated through the nuclear receptors, liver X recep-
tor (LXR) α and PPAR γ [19]. Besides that, HMG-CoA re-
ductase (HMGCR), a rate-limiting enzyme for cholesterol
synthesis, can also exerts its regulation effect on choles-
terol synthesis at the transcriptional level [20]. It is related
with the free cholesterol (FC) level of macrophage
[21, 22]. When inflow and esterification of cholesterol
increase and/or its outflow decrease, excessive esterified
cholesterol (CE) will accumulate as lipid droplets in mac-
rophages, thereby contributing to the formation of foam
cells which initiate atherosclerosis.
Our previous study has found that AGEs-RAGE axis
can increase the lipid droplets accumulation in the aor-
tas of diabetic rats [23]. In that study, we observed obvi-
ous lipid droplets in the cytoplasm of smooth muscle
cells and basal membrane of aortas when there were not
any classical pathological changes of atherosclerosis can
be seen by HE stainning in high-diet fed diabetic Goto
Kakisaki (GK) rats. The expression of RAGE was also
increased in aortas of GK rats. Recent experimental evi-
dence also suggests that AGEs may promote foam cells
formation [24–26]. However, the roles of AGEs in influ-
encing the uptake, synthesis and efflux of cholesterol in
macrophages and the underlying mechanisms are poorly
understood. In the present study, we intended to investigate
the effect of AGEs on lipid accumulation in macrophages
stimulated with oxidized-LDL (oxLDL). Furthermore, we
investigated the effects of AGEs-RAGE interaction on regu-
lating cellular cholesterol efflux, influx, and esterification in
THP-1 macrophages. This study will provide a new strategy
for the treatment of diabetic atherosclerosis.
Methods
Preparation of model AGEs
BSA and D-glucose (Sigma, USA) were dissolved in
phosphate-buffered saline PBS (pH 7.2–7.4), and the final
concentrations of BSA and D-glucose was 5 g/L and
50 mmol/L, respectively. EDTA was added to a final con-
centration of 0.5 mmol/L to reduce oxidation. Penicillin
(100 U/L) and streptomycin (100 μg/ml) were added to
the reaction mixture to prevent bacterial contamination.
The reaction mixture was filtered through 0.22 μm filter
and then incubated in electrothermal incubation at 37 °C
for 12 weeks. At the end of the incubation period, the
reaction mixture was dialyzed against sterilized PBS
(pH 7.2–7.4) to remove the unconjugated glucose; the
glucose in the dialyzate was <0.03 mmol/L. The reaction
mixture was measured in a fluorospectrophotometer with
an excitation wave of 370 nm, and the maximum ab-
sorption peak was measured at 440 nm to verify that
the mixture was AGE-BSA. Finally, the AGE-BSA was
freeze-dried and stored at 4 °C.
Cell culture and treatment
Human monocytic cell line THP-1 was purchased from
Scientific Research Institute, Shanghai, China and cultured
in RPMI 1640 medium containing 10 % FBS, 10 mM
HEPES (Sigma, USA), and 1 % pen/strep solution at a
density of 5 × 105cells/ml in a 5 % CO2 incubator. The
cells were seeded in six-well plates for 48 h in the pres-
ence of 100 ng/ml PMA, (Sigma, USA) which allowed
Xu et al. Lipids in Health and Disease  (2016) 15:161 Page 2 of 13
them to differentiate into adherent macrophages. The
culture medium was then changed into RPMI1640
medium containing 0.1 % FBS for 6 h of cell starvation.
The macrophages were pretreated with BSA (600 μg/ml)
as control group or with different concentration of AGEs
(300 μg/ml and 600 μg/ml) for 2 h, then stimulated with
oxLDL (100 μg/ml) (Jingke Chemistry, China) for 24 h at
4 °C in a 5 % CO2 incubator, and then collected for detec-
tion. To observe the effect of RAGE, one group of cells
was treated with anti-RAGE antibody (10 μg/ml)(Abcam,
USA) for 2 h before adding high concentration of AGEs
(600 μg/ml).
Oil red O staining
After the above mentioned treatment, the cells were col-
lected, washed twice with ice-cold PBS, and then fixed
with 10 % neutral-buffered formalin for 15 min. The
cells were washed again with 60 % isopropyl alcohol for
1 min and then stained with oil red O (Sigma, USA) for
15 min. The oil red O was discarded, and excess dye was
washed away with 60 % isopropyl alcohol. After washing
with distilled water, the specimens of each group were
placed under an inverted microscope to observe oil red
staining. Cellular lipid accumulation was quantified by
the optical density(OD) at 518 nm of Oil Red O extracted
from stained cells using isopropanol. The results were
normalized as OD value/number of cells.
RNA isolation and quantitative RT-PCR
Total RNA was isolated using Trizol reagent (Invitrogen,
CA). For reverse transcription, 2 μg of the total RNA
was converted to first strand complementary DNA in
20 μl reactions using a reverse transcription kit (Thermo,
USA). Quantitative real-time PCR analysis was performed
(StepOne, Applied Biosystems) using SYBR Green
(Takara, JAP). The thermal cycling program was 10 min
at 95 °C for enzyme activation and 40 cycles of denatur-
ation for 15 s at 95 °C, 5 min at 60 °C for annealing and
extension. The comparative cycle threshold (CT) method
was used to determine relative mRNA expression of
genes as normalized by GAPDH housekeeping gene.
Gene expression was determined by the 2-ΔΔCt method.
Primers used were as follows: 5’-GAAACTGAACACA
GGCCGGA-3’ for RAGE-F, 5’- CACGGACTCGGTAG
TTGGAC-3’ for RAGE - R; 5’ – TAAGATCAGGTGGG
TTGGGC -3’ for SRA2-F; 5’ –CAGGTACAACACGG
GAACCA -3’ for SRA2-R; 5’ –TCCTCTGGCAACA
AACCACA-3’ for CD36-F; 5’ –AAGTCCTACACT GC
AGTCCTC -3’ for CD36-R; 5’ –TGTCTGATGGCCG
CTTTCT -3’ for ABCG1-F; 5’ –CACCTCATCCACCG
AGACAC -3’ for ABCG1-R; 5’ –AGGGAGAG CACA
GGCTTTGAC -3’ for ABCA1-F; 5’ –CCCCACTCAC
TCTCGCTCG -3’ for ABCA1-R; 5’ –TCTTATTGGTC
GAAGGCTCGT -3’ for HMGCR-F; 5’ –TCTCACT
AGAGGCCACCGAA -3’ for HMGCR-R; 5’ –AGCC
AAGGTACAGGTAACGA -3’ for LXRα-F; 5’ –GATTA
CAACGGTGATGGCGG -3’ for - LXRαR; 5’ –TAG
TCTACGCCTGTGGAGCC -3’ for ACAT-1-F; 5’ –TC
TTATTTCCTG CACCAGCCTC -3’ for – ACAT-1- R;
5’ –GTAAACACGCTCCTCTAA -3’ for GAPDH-F;
5’ –TGACGGGATCTCGCTCCTGGAAGAT -3’ for
GAPDH- R.
Protein isolation and Western blot analysis
After treatment of cells as indicated above, cells were
lysed with RIPA lysis buffer (50 mmol/L Tris pH 7.5,
150 mmol/L NaCl, 1 mmol/L EDTA, 1 % Triton X-100,
1 % sodium deoxycholate, 0.1 % SDS) containing prote-
ase inhibitor cocktail (Sigma, USA), and protein concen-
trations of lysates determined by the BCA assay kit
(Beyotime, China). Proteins (20 μg of extracts) were
electrophoresed by 12 % SDS-PAGE, and transferred to
a nitrocellulose membrane. The membranes were blocked
overnight at 4 °C in 5 % skim milk, and then incubated
with primary antibodies against for RAGE, SRA2, CD36,
ABCA1, ABCG1, LXRα, HMGCR and ACAT1 (1:1000),
(Abcam, USA) 2 h at room temperature. The membranes
were washed with TBS-T, and incubated with a horse-
radish peroxidase conjugated secondary anti-mouse or
anti-rabbit IgG antibody (1:5000, Bioss, China) for 1 h
at 37 °C. Afterwards blots were developed using ECL
Plus. The signal intensities of specific bands were detected
with a Clinx ChemiScope imaging-system (Qinxiang, China)
and quantified using TotalLab TL100-Quick Start analysis
software.
Measurement of intracellular cholesterol and cholesterol
esterification
After treatment of cells as indicated above, cells were
washed twice with PBS, cellular lipids extracted with a
mixture of hexane and isopropanol (3:2 v/v), and lipid
extracts dried under a stream of nitrogen. Total choles-
terol (TC) and FC concentrations were determined using
enzymatic assay kit (Applygene Technologies Inc, China)
in accordance with the manufacturer’s instructions. The
concentration of CE was determined by subtraction of
the concentration of free cholesterol from that of total
cholesterol. Cholesterol concentrations were related to
cellular protein as determined by the BCA protein assay
kit (Beyotime, China). Cellular protein was obtained by
lysis of cells in 0.2 mol/L NaOH after extraction of cellular
lipids. Results are expressed as lipids/mg cellular protein.
Cholesterol uptake assay
The treated macrophages were incubated with 1,1’-
dioctadecyl- 3,3,3’,3’ -tetramethylin docarbocyaninet (Dil)-
oxLDL (40 μg/ml) (Jingke Chemistry, China) instead of
oxLDL for 24 h. After the medium was removed, cells
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were washed twice with PBS. The specimens of each
group were placed under an inverted fluorescence micro-
scope (OLYMPUS, CKX41, JAP). Fluorescence intensity
was expressed as Mean fluorescence intensity (MFI)/
number of cells, and MFI was caculated by the cumula-
tive fluorescence density/area analysed by Image-Pro
Plus 6.0. Fluorescent intensity was quantified from at
least 3 random fields (1024 × 1024 pixels) per slide, from 3
slides per experimental condition and graphed.
Cholesterol efflux assay
The treated macrophages were plated in 12-well plates
and loaded with 40 μg/ml Dil-oxLDL for 48 h at room
temperature. Then the medium was removed and cells
were washed twice with PBS. The culture medium was
then changed into RPMI1640 medium containing 0.1 %
BSA supplemented with apoAI (10 μg/ml, Novoprotein,
China) or HDL (100 μg/ml, Jingke Chemistry, China) at
37 °C for 24 h. At the end of this incubation period, the
supernatant was collected and centrifuged at 12,000 rpm
for 10 min to remove debris. Cells were lysed with
0.5 mL of 0.1 N NaOH. The fluorescence in both the
supernatant and cellular lipid was measured on a fluor-
escence microplate (Thermo Labsystems, USA). Fluores-
cence intensity was determined and expressed as a
percentage of the total cell Dil-oxLDL content (effluxed
Dil-oxLDL plus cell-associated Dil-oxLDL).
Statistical analysis
Data are expressed as mean ± SD. Results were analyzed
by oneway ANOVA followed by Fisher's LSD procedure
using SPSS 21.0. P < 0.05 was considered statistically sig-
nificant. All experiments were performed at least three
times.
Results
AGEs-induced up-regulation of RAGE expression in THP-1
macrophages
After incubation with AGEs at different concentrations
(300 μg/ml and 600 μg/ml), RAGE expression was
substantially up-regulated both in mRNA (Fig. 1a) and
protein (Fig. 1b) compared with control group in a
concentration-dependent manner. There were 3.0-fold
increase in mRNA (3.53 ± 0.57 vs 1.15 ± 0.07, P = 0.049)
and 2.5-fold increase in proteins (2.52 ± 0.49 vs 1.02 ±
0.01, P < 0.001) compared with control group when the
concentration of AGEs was 300 μg/ml. As the concentra-
tion of AGEs reaching at 600 μg/ml, increasement of
RAGE expression was 17.0 times in mRNA (19.5 ± 0.43 vs
1.15 ± 0.07, P < 0.001) and 4.0 times in proteins (4.07 ±
0.43 vs 1.02 ± 0.01, P < 0.001) compared with control
group. After pretreating with anti-RAGE antibody, RAGE
expression was suppressed both in mRNA (5.70 ± 0.45 vs
19.5 ± 0.43, P < 0.001) (Fig. 1a) and protein (1.24 ± 0.31 vs
4.07 ± 0.43, P < 0.001) (Fig. 1b) compared with 600 μg/ml
AGEs group.
AGEs increase the oxLDL-induced lipid accumulation in
THP-1 macrophages
Intracellular lipid droplets were observed through oil
red staining. As shown in Fig. 2a–d, AGEs-stimulated
macrophages showed much more red-stained lipid
droplets than the control group, especially in the group
of 600 μg/ml AGEs. However, this trend was inhibited
by anti-RAGE antibody pretreatment. The optical dens-
ity (OD) value of each group which was normalized by
the number of cells showed that there was significant
change in 600 ug/ml AGEs group compared with con-
trol group and anti-RAGE antibody pretreated group
(Fig. 2 e).
AGEs increase lipid uptake in THP-1 macrophages by
up-regulating CD36, SRA2 expression mediated by RAGE
To investigate the effects of AGEs on cholesterol uptake
in macrophages, we examined cholesterol uptake using a
Dil-oxLDL binding assay in response to the treatments
with AGEs at the concentrations of 300 μg/ml and
600 μg/ml in THP-1 macrophages. As shown in Fig. 3a–c)
and (e), AGEs at a concentration of 300 μg/ml did not
significantly alter Dil-oxLDL binding to THP-1 macro-
phages (0.093 ± 0.012 vs 0.085 ± 0.012, P = 0.335), while
600 μg/ml AGEs significantly increased oxLDL intern-
alization in THP-1 macrophages (0.156 ± 0.023 vs
0.085 ± 0.012, P < 0.001). Pretreatment with anti-RAGE
antibody before adding AGEs in concentration of 600 μg/
ml reduced Dil-oxLDL binding to THP-1 macrophages
compared with only AGEs (0.103 ± 0.013 vs 0.156 ± 0.023,
P < 0.001) (Fig. 3d, e).
Macrophages phagocytose oxLDL through scavenger
receptors, including CD36, and scavenger receptor A, to
form foam cells. To elucidate the molecular mechanism
of AGEs on the accumulation of oxLDL in macrophages,
we detected the expression of scavenger receptors, CD36
and SRA2. As depicted in Fig. 4, AGEs in concentration
of 600 μg/ml can dramatically increase CD36 and SRA2
mRNA and protein levels (P <0.05); whereas, those
changes can’t be observed in cells incubated with 300 μg/ml
AGEs. The application of antibody of RAGE significantly
suppressed the expression of CD36 and SRA2 both in
mRNA and protein compared with only AGEs of 600 μg/ml
(P <0.05) (Fig. 4).
AGEs reduce ABCG1-dependent cholesterol efflux to HDL
through interaction with RAGE
We next investigated the effect of AGEs on cholesterol
efflux. By using Dil-oxLDL, we found that AGEs in con-
centration of 600 μg/ml elicited a significant reduction
in cholesterol efflux mediated by HDL but not apoAI,
Xu et al. Lipids in Health and Disease  (2016) 15:161 Page 4 of 13
expressed as the percentage of total cell cholesterol re-
leased into the medium (P < 0.05). Treatment with anti-
body of RAGE significantly increased cholesterol efflux
(P < 0.05). (Fig. 5)
Then we examined the expression of both ABCA1
and ABCG1 in macrophages. AGEs significantly reduced
the mRNA expression of ABCG1 but not ABCA1 in con-
centration- depended manner (300 μg/ml (0.38 ± 0.03 vs
1.15 ± 0.07,P < 0.001) and 600 μg/ml of AGEs (0.09 ± 0.01
vs 1.15 ± 0.07,P < 0.001) (Fig. 6a, b). Pretreating THP-1
macrophages with an anti-RAGE antibody significantly
suppressed this effect (Fig. 6b). The expression of ABCG1
in protein was in accordance with that in mRNA (Fig. 6e).
Then we examined the potential involvement of tran-
scription factors LXR-α, known regulators of ABCA1 and
ABCG1 expression in macrophages. We found that ex-
pression of LXR-α was up-regulated both in mRNA and
in protein in incubation with AGEs, and the pretreatment
with anti-RAGE antibody suppressed the effect (Fig. 6c, f ).
AGEs increase cholesteryl ester formation by targeting
ACAT1 and HMGCR through regulating RAGE expression
We measured the levels of TC and FC by enzymatic assay
kit and calculated the levels of CE. The data (Table 1)
showed that 600 μg/ml of AGEs treatment increased CE
levels compared with the control group (P < 0.001).
However, pretreatment with anti-RAGE antibody inhib-
ited AGEs-induced foam cell formation (P < 0.05). We
further investigated the expression of HMGCR and
ACAT-1, which were related with the endogenous syn-
thesis and esterification of FC in THP-1 macrophages.
AGEs significantly reduced ACAT1 mRNA expression
in a high concentration of 600 μg/ml (8.15 ± 1.45 vs
1.15 ± 0.07,P < 0.001) but reduced ACAT1 protein levels
even in a low concentration of 300 μg/ml (4.93 ± 0.23
vs 1.02 ± 0.06,P < 0.001) (Fig. 7a, c). The expressions of
HMGCR in mRNA and protein were increased in con-
centration of 600 μg/ml of AGEs (P < 0.05) (Fig. 7b, d).
Pretreatment with anti-RAGE antibody showed the
Fig. 1 Effect of AGEs on RAGE expression in macrophages. a The mRNA expression of RAGE was determined using quantitative real-time PCR;
b Protein expression of RAGE in each group was analyzed by Western blot. GAPDH demonstrated equal loading. The right panel shows the
average densitometric analysis of three independent experiments. Data represent mean ± SD, from three independent experiments, each performed in
triplicate. *P < 0.05 vs. control group. ΔP < 0.05 vs. 600 μg/ml AGEs group
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opposite effect, significantly decreasing ACAT1 and
HMGCR levels (Fig. 7a–d).
Discussion
The maintain of macrophage cholesterol homeostasis is
of great importance in the prevention of atherosclerosis.
Dysregulation of the balance of cholesterol influx, en-
dogenous synthesis, esterification/hydrolysis, and choles-
terol efflux leads to excessive accumulation of cholesterol
in macrophages and their transformation into foam cells
and death [15]. In the present study, we elucidated the
underlying mechanisms of AGEs-RAGE regulated cellular
influx, intracellular esterification/hydrolysis and efflux of
cholesterol. Our results provide strong evidence that
AGEs-RAGE interaction may regulate the processes of
cholesterol homeostasis from influx to efflux by increasing
the expression of SRA2, CD36, ACAT1, HMGCR and de-
creasing expression of ABCG1 in macrophages.
There is increasing evidence that AGEs and their inter-
action with RAGE play a pivotal role in atherosclerosis, in
particular in the setting of diabetes. AGEs binding to
RAGE activates various signalling pathways, including
NADPH oxidases, mitogen-activated protein kinases
(MAPKs), p21ras, ERK p38 and protein kinase C (PKC),
and finally leads to sustained cellular dysfunction driven
by long-term activation of the nuclear factor-kB (NF-
kB) [27, 28]. The importance of AGEs as downstream
mediators of hyperglycaemia in diabetes has been
amply demonstrated by animal studies using inhibitors
of advanced glycation to retard the development of
vascular disease without directly influencing plasma
glucose levels [29, 30]. Furthermore, dietary excess of
AGEs has been shown to accelerate atherosclerosis
without affecting glycaemic control [31]. Studies in vivo
showed that administration of soluble RAGE (sRAGE), a
truncated form of RAGE acting as a decoy for AGE,
completely suppressed diabetic atherosclerosis in
glycemia- and lipid-independent manners [13]. In diabetes-
associated atherosclerosis models, RAGE overexpression in
transgenic mice was associated with increased vascular
Fig. 2 AGEs increase lipid accumulation in macrophages in a concentration-dependent manner. a–d Representative images of oil red staining.
a control group; b AGEs of 300 μg/ml group; c AGEs of 600 μg/ml group; d AGEs of 600 μg/ml plus anti-RAGE antibody group. The magnification
of each panel is 200×. e Quantification of Oil Red O stained cells as measured by the OD value at 518 nm. The results were normalized as OD
value/number of cells. Data represent mean ± SD. from three independent experiments, each performed in triplicate. *P < 0.05 vs. 600 μg/ml
AGEs group. One of three representative experiments is shown
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injury, while RAGE deletion conferred partial vascular
protection [32].
Despite the important contribution of AGE to the accel-
erated atherosclerosis in diabetes, the specific molecular
mechanisms in response to AGE within macrophages (a
central player in atherogenesis) remain unclear. In this
study, we discovered that exposure of THP-1 macro-
phages to AGEs was concentration-dependently associ-
ated with lipid accumulation observed by oil O stain and
intracellular CE/TC determination. At the same time, the
expression of RAGE elevated in parallel with the increase
of lipid accumulation. RAGE specific antibody led to re-
versions in lipid contents in macrophages, suggesting that
AGE-elicited atherogenic effects in macrophages were, at
least partly, RAGE-dependent. These observations suggest
that excessive formation of AGEs could render diabetic
patients under high risk of developing atherosclerosis.
The Dil-oxLDL binding assay in our study showed
that AGEs increased the binding of Dil-oxLDL to mac-
rophages, indicating that AGEs promote cholesterol uptake.
Cholesterol uptake is a pathway by which extracellular
modified LDL are ingested by macrophages via receptors-
mediated phagocytosis and pinocytosis. SRs such as SR-A
and CD36 have been implicated in this process. In vitro
studies have shown that CD36 and SR-A account for
75–90 % of ox-LDL internalization by macrophages,
whereas other SRs cannot compensate for their absence
[33]. In present study we found AGEs can upregulated
SRA2 and CD36 mRNA and protein levels, indicating
that AGEs may promote cholesterol uptake by increas-
ing SRA2 and CD36 expression. It has been reported
that AGEs only without interacting with RAGE can up-
regulate the expression of SRA2 and CD36 [34, 35].
However, It was not the same in our study. After block-
ade of RAGE by specific antibody, we found that SRA2
and CD36 expression decreased significantly accompanied
with the reduction of cholesterol uptake, suggesting that
AGEs increase cholesterol uptake of macrophages mainly
through binding with RAGE. A unique feature of CD36 is
that expression of its gene could be regulated by ligands
Fig. 3 AGEs increase oxLDL uptake in macrophages. a–d Cells were analyzed on a OLYMPUS inverted fluorescence microscope system and
presented as photomicrographs. a control group; b 300 μg/ml AGEs group; c 600 μg/ml AGEs group; d 600 μg/ml AGEs plus anti-RAGE antibody
group. e Quantification of fluorescent intensity of cells as MFI/number of cells. Data represent mean ± SD, from three independent experiments.
Fluorescent intensity was quantified from at least 3 random fields (1024 × 1024 pixels) per slide, from 3 slides per experimental condition and
graphed. * P < 0.05 vs. control group. ΔP < 0.05 vs. 600 μg/ml AGEs group. One of three representative experiments is shown
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via PPAR-γ dependent signaling pathway, and SRA-2 is
mainly regulated by PPAR-γ and NF-kB signaling pathway
[33]. Activation of RAGE with AGEs leads to the produc-
tion of reactive oxygen (ROS) and nitrogen species (RNS)
by a variety of mechanisms, which may activates the
PPAR-γ and NF-kB signaling pathway [24] [36]. It may be
the molecular mechanism for upregulation of CD36 and
SRA2 by AGEs-RAGE interaction.
The results of cholesterol efflux assay in our study
showed that AGEs can reduce cholesterol efflux through
HDL but not apo AI in macrophages. When blocking
AGEs-RAGE interaction by anti-RAGE antibody, the
decrease of cholesterol efflux would recover. It is con-
firmed that AGEs have deleterious effects on choles-
terol efflux in macrophages through binding with
RAGE. Then we determined the transporters associated
Fig. 4 AGEs upregulate CD36, SRA2 expression in macrophages. The expression of CD36, SRA2 mRNA (a, b) and protein (c, d) were determined
using real-time quantitative PCR and western blotting assays, respectively. All the results were expressed as mean ± SD, from three independent
experiments, each performed in triplicate. *P < 0.05 vs. control group. ΔP < 0.05 vs. 600 μg/ml AGEs group
Fig. 5 AGEs decreased cholesterol efflux to HDL but not to apoAI in macrophages. Fluorescence intensity was determined and expressed as a
percentage of the total cell Dil-oxLDL content. Data represent mean ± SD, from three independent experiments, each performed in triplicate.
*P < 0.05 vs. control group
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Fig. 6 AGEs downregulate ABCG1 expression in macrophages. The expression of ABCA1, ABCG1, LXR-α mRNA (a–c) and protein (d–f) were
determined using real-time quantitative PCR and western blotting assays, respectively. All the results are expressed as mean ± SD, from three
independent experiments, each performed in triplicate. *P < 0.05 vs. control group. ΔP < 0.05 vs. 600 μg/ml of AGEs group
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with cholesterol efflux and found that AGEs decreased
ABCG1 mRNA and protein levels in macrophages in a
RAGE-dependent manner.
Reverse cholesterol transport (RCT) is the primary path-
way for the removal of excess cholesterol and involves
lipid transporters such as ABCA1 and ABCG1 that me-
diate the transfer of cholesterol from peripheral cells to
selected extracellular acceptors [37, 38]. The full ABC
transporter ABCA1 appears most effective at mediating
cholesterol efflux to apoAI as acceptor [39, 40]. The
Table 1 Effects of AGEs on cholesterol content in macrophages. (ng/μg protein)
Control 300 μg/ml of AGEs 600 μg/ml of AGEs 600 μg/ml of AGEs + Anti-RAGE antibody
TC 197.13 ± 22.1** 234.43 ± 11.23** 652.61 ± 11.76* 407.78 ± 33.98*, **
FC 163.21 ± 7.42** 201.83 ± 12.44** 458.70 ± 29.14* 284.20 ± 33.57*, **
CE 33.92 ± 29.49** 32.6 ± 20.02** 193.91 ± 31.39* 123.58 ± 65.19*, **
Data are expressed as mean ± S.D. *P < 0.05 vs. control group, **P < 0.05 vs. 600 μg/ml of AGEs group
Fig. 7 AGEs upregulate ACAT-1, HMGCR expression in macrophages. The expression of ACAT-1, HMGCR mRNA (a, b) and protein (c, d) were
determined using real-time quantitative PCR and western blotting assays, respectively. All the results are expressed as mean ± SD, from three
independent experiments, each performed in triplicate. *P < 0.05 vs. control group. ΔP < 0.05 vs. 600 μg/ml AGEs group
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“half transporter” ABCG1 also facilitates cholesterol
efflux from macrophages, preferring HDL as acceptor
[41, 42]. LXR can control the expression of both ABCA1
and ABCG1 [43], and several recent reports suggest that
both transporters share similar transcriptional control
mechanisms [44, 45]. The effects of AGEs-RAGE axis on
ABC transporters reported in previous studies are contra-
dictory. The results of Passarelli M et al. [46] have shown
that AGEs can impair cholesterol efflux from cultured hu-
man fibroblasts and murine macrophages through sup-
pressing ABCA1 expression [46]. However, Isoda K et al.
[47] reported that AGEs reduced macrophage cholesterol
efflux to HDL through decreasing ABCG1 expression in a
LXR-α independent way [47]. Recent study from Daffu G
et al. [48] have demonstrated that RAGE suppressed
macrophage cholesterol efflux in diabetic animal models
and several different cell lines by moderately upregulating
ABCA1 expression and significantly upregulating ABCG1
expression in a LXRα-independent way [48]. Our results
were more like Daffu G’s that ABCA1 expression was
slightly changed without statistical significance after treat-
ment, while ABCG1 expression was dramatically changed
with obviously statistical significance. LXR-α expression
was contrary to both ABCA1 and ABCG1. So we report
here that AGEs mainly reduces the expression of ABCG1
but not ABCA1 in a LXRα-independent manner in THP-
1 macrophages, supporting the notion that ABCG1 may
be especially important in diabetic atherosclerosis and
providing a novel mechanistic insight into the relationship
between HDL and atherosclerosis risk in diabetic patients.
Our results also provide evidence that there are other sig-
naling pathway to regulate expression of ABCG1 except
LXR-α. Peroxisome proliferator response elements (PPRE)
in the promoter regions of target genes is recognized as a
important regulator which can binging with PPAR-γ to
activate transcription [49]. It has been demonstrated
that RAGE ligands suppressed ABCG1 and ABCA1
promoter luciferase activity and transcription of ABCG1
and ABCA1 through PPRE but not LXR elements [48]. So
it can be speculated from our results that AGEs-RAGE
axis may regulate ABCG1 expression mainly through
PPRE binding with PPAR-γ, while ABCA1 expression may
be mainly controlled by classical PPAR-γ/LXR-α signaling
pathway which is less affected by AGEs-RAGE axis.
Besides PPRE, previous findings suggest a hitherto un-
suspected degree of complexity in the regulation of the
ABCG1 gene. The human ABCG1 gene spans 97 kb
comprising 20 exons, potentially giving rise to multiple
transcripts, and further contains two promoters with
binding sites for multiple transcription factors, including
NF-kB and sterol regulatory element-binding protein
(SREBP) [50]. Both SREBP and NF-kB have been shown
to be involved in the coactivation of transcription of genes
involved in cholesterol metabolism [51]. Such structural
complexity raise speculation about the potential mechan-
ism that AGEs-RAGE axis interfere with the expression of
ABCG1 through NF-kB and SREBP signaling pathway.
Further studies will be required to elucidate the details of
AGEs-RAGE-NF-kB/ SREBP-ABCG1 regulating pathway.
In the process of foam cell formation, ACAT1 re-esterifies
excess FC to promote the biosynthesis of CE that is stored
in lipid droplets [52]. In this study, we found that AGEs in-
creased cellular CE levels. Furthermore, we demonstrated
that high concentration of AGEs targeted expression of
ACAT1, regulated the mRNA and protein levels of ACAT1,
and increased CE formation in macrophage-derived foam
cells. In contrast, low concentration of AGEs increased the
protein expression of ACAT1 but had no effect on its
mRNA expression, which can’t be explained by present
study. However, it should be noted that ACAT1 protein
increased similarly after treatment with 300 and
600 μg/ml AGEs, but the CE levels didn’t increase over
control at 300 μg/ml AGEs. The possible reseason for
that may be the difference of internalization of lipopro-
teins by macrophages between 300 and 600 μg/ml
AGEs group. Besides, we didn’t detect the expression of
nCEH which hydrolyzes CE to cholesterol for efflux out
of the cells. The changes of nCEH caused by different
concentration of AGEs can also affect the levels of CE.
In addition to uptake of extracellular lipoprotein, another
main sources of intracellular FC are endogenous synthesis,
which is regulated by HMGCR, a rate-limiting enzyme in
the pathway for cholesterol synthesis [53]. Our study
have demonstrated that AGEs can upregulate expression
of HMGCR which can increase intracellular cholesterol
and promote CE formation. Both ACAT1 expression and
HMGCR expression decreased when using anti-RAGE
antibody to pretreat, which indicated that the role of
AGEs in upregulating ACAT1 and HMGCR needed to
bind with RAGE. SREBP2 is probably the key factor
connecting AGEs/RAGE with ACAT1/HMGCR [54].
Conclusions
In conclusion, the present study shows that AGEs in-
crease lipids accumulation in macrophages probably by
upregulating RAGE expression. The whole process of
foam cell formation including cholesterol influx, synthesis
and efflux in macrophage can be affected by AGEs-RAGE
interaction. Our study provide a deep understanding how
AGEs can accelerate diabetic atherogenesis and suggest
that drugs for anti-AGEs, downregulating expression of
RAGE or blocking AGEs binding with RAGE may be use-
ful adjunctive therapeutic agents in the management of
diabetic atherosclerosis especially in the early stage to pre-
vent foam cell formation. According to the results that
most of the changes induced by AGEs are concentration
dependent, our study emphasize the importance of good
blood glucose control which can reduce AGEs levels both
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in blood serum and in arterial wall in prevention of dia-
betic atherosclerosis. It is also indicated that HDL may
have special meaning for diabetic patients compare
with non-diabetic people. Further studies need to be
done to understand the detailed signaling pathways
whereby AGEs-RAGE breaks the homeostasis of chol-
esterol metabolism in macrophages.
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